{"schema_version":"secwatch.filing_event.v1","accession":"0000885725-24-000050","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.302257+00:00","generated_at":"2026-06-02T04:31:30.951152+00:00","sec_items":["5.02","5.03","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Boston Scientific appoints Dr. Cheryl Pegus to board; amends $2.75B credit facility","bullets":["Dr. Cheryl Pegus elected to board as tenth director, effective May 8, 2024; will serve on compensation and risk committees.","Pegus brings 25+ years of clinical and business leadership; most recently partner at Morgan Health, formerly EVP at Walmart and CMO at Walgreens.","Company amended its $2.75B revolving credit agreement, extending maturity to May 2029 for consenting lenders and adjusting the pricing grid.","Reset EBITDA exclusion cap for restructuring charges to $500M since March 31, 2024 (previously December 31, 2022)."],"urls":{"canonical":"https://secwatch.observer/filing/0000885725-24-000050","json":"https://secwatch.observer/filing/0000885725-24-000050.json","markdown":"https://secwatch.observer/filing/0000885725-24-000050.md","text":"https://secwatch.observer/filing/0000885725-24-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000050/0000885725-24-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000050/bsx-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:31:30.951152+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"82f8fa1ee2","claim":"Cheryl Pegus was appointed as Director at BOSTON SCIENTIFIC CORP.","evidence_excerpt":"appointed Cheryl Pegus, MD, MPH, to be a director of the Company, to hold office until the next annual meeting of stockholders, effective May 8, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000050/0000885725-24-000050-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}